Jak3 contributes to the activation of ALK and Stat3 in ALK+ anaplastic large cell lymphoma [1]

Laboratory Investigation

Volumn 86, Issue 4, 2006, Pages 417-419

  Amin, Hesham M ^a   Lin, Quan ^a   Lai, Raymond ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMO 4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; CORRELATION ANALYSIS; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HYPOTHESIS; LARGE CELL LYMPHOMA; LETTER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STATISTICAL SIGNIFICANCE;

CELL LINE, TUMOR; HUMANS; JANUS KINASE 3; LYMPHOMA, T-CELL; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RESEARCH DESIGN; STAT3 TRANSCRIPTION FACTOR;

EID: 33645276549     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700393     Document Type: Letter

References (17)

1. Marzec M, Kasprzycka M, Ptasznki A, et al. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 2005;85:1544-1554.
2. Amin HM, Medeiros LJ, Ma Y, et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003;22:5399-5407.
3. Crockett DK, Lin Z, Elenitoba-Johnson KSJ, et al. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 2004;23:2617-2629.
4. Leon F, Cespon C, Franco A, et al. SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implication in JAK3-mediated signaling. Leukemia 2002;16:1470-1477.
5. Zhang Q, Raghunath PN, Vonderheid E, et al. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 2000;157:1137-1146.
6. Khoury JD, Rassidakis GZ, Medeiros LJ, et al. Methylation of SHP1 and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood 2004;104:1580-1581.
7. Lai R, Rassidakis GZ, Lin Q, et al. Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum Pathol 2005;36:939-944.
8. Sudbeck EA, Liu XP, Narla RK, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999;5:1569-1582.
9. Boggon TJ, Li Y, Manley PW, et al. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 2005;106:996-1002.
10. Jiang N, He T-C, Miyajima A, et al. The box1 domain of the erythropoietin receptor specifies Janus kinase 2 activation and functions mitogenically within an interleukin 2 β-receptor chimera. J Biol Chem 1996;271:16472-16476.
11. Habib T, Senadheera S, Weinberg K, et al. The common γ chain (γc) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via Jak3. Biochemistry 2002;41:8725-8731.
12. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-878.
13. Moriguchi M, Hissong BD, Gadina M, et al. CXCL12 signaling is independent of Jak2 and Jak3. J Biol Chem 2005;280:17408-17414.
14. Johnston JA, Bacon CM, Finbloom DS, et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukin 2 and 15. Proc Natl Acad Sci USA 1995;92:8705-8709.
15. Zhou Y-J, Magnuson KS, Cheng TP, et al. Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of Syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation. Mol Cell Biol 2000;20:4371-4380.
16. Tibbles HE, Vassilev A, Wedorf H, et al. Role of JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J Biol Chem 2001;276:17815-17822.
17. Zhang Q, Raghunath PN, Xue L, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 2002;168:466-474.